Covaxin, a vaccine developed by government’s medical research agency and Bharat Biotech International Ltd., was found to have a 77.8% efficacy rate against symptomatic Covid-19 in a long-awaited analysis published in The Lancet.
According to the study, efficacy data of the whole virion-inactivated vaccine further demonstrates 63.6% protection against asymptomatic disease and 65.2% protection against the B.1.617.2 Delta variant.
“The Lancet peer review confirms the efficacy analysis that demonstrates Covaxin to be effective against Covid-19. Covaxin is the only Covid-19 vaccine to have demonstrated efficacy data from Phase 3 clinical trials against the Delta variant at 65.2%, 90.1% effective against the Kappa variant”, Lancet said Bharat Biotech in a statement after The Lancet published the study on Friday.
Also Read: No change in fuel prices on November 13
“BBV152 was well tolerated; the same proportion of participants reported adverse events in the vaccine group [1597 out of 12879 (12.4%)] and placebo group [1597 of 12874 (12.4%)] with no clinically significant differences in the distributions of solicited, unsolicited, or serious adverse events between the groups, and no cases of anaphylaxis or vaccine-related deaths,” the peer-reviewed journal observed.
Covaxin safety analysis demonstrates that the adverse events reported were similar to placebo, with 12% of the subjects experiencing commonly known side effects and less than 0.5% of subjects experiencing serious adverse events, Bharat Biotech said, adding: “Covaxin was well tolerated and the Data Safety Monitoring Board has not reported any safety concerns related to the vaccine. The overall rate of adverse events observed in Covaxin was lower than that seen in Covid-19 vaccines. The safety profile of Covaxin is now well established”.
(With inputs from agencies)
